AURA3

NCT02151981 📎

Regimen

Experimental
osimertinib
Control
platinum+pemetrexed

Population

T790M+ NSCLC after 1st/2nd-gen TKI progression

Key finding

mPFS 10.1 vs 4.4 mo, HR 0.30 (0.23-0.41); established osimertinib for T790M resistance

Source: PMID 27959700

Timeline

  • Enrollment start: 2014-08-04 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source